Novo's semaglutide handily whips Eli Lilly's Trulicity in a PhIII diabetes showdown
Novo Nordisk had some more upbeat pipeline news to report Wednesday afternoon, as researchers rolled out new Phase III data showing their GLP-1 drug semaglutide — a would-be blockbuster — beat out Eli Lilly’s Trulicity (dulaglutide) in a head-to-head showdown.
Of particular note: Novo’s drug sailed through SUSTAIN 7 with comparable instances of diabetic retinopathy with the comparator drug from Lilly. That may help qualm fears raised by earlier study results.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
